Parental acceptability of emerging respiratory syncytial virus (RSV) immunization strategies in Canada

Respiratory syncytial virus (RSV) can pose a serious health risk to infants. This study is exploring the views and experiences of expectant parents about immunizing infants against RSV, and ways information about RSV could be shared with parents.

RSV is a virus that affects the lungs. It usually causes mild, cold-like symptoms. But it can be serious, especially for infants because their immune system is not fully mature.  Two main options now exist to help prevent infants from getting severe RSV. One is an antibody product given to the infant (nirsevimab). The other is a vaccine for pregnant people to help protect their baby after birth (Abrysvo).

To participate in this study, you must:

• live in a province in Canada
• be pregnant or be the spouse/partner of a pregnant individual
• be between the ages of 18 and 64

Participation involves completing a brief demographic questionnaire completed online (approximately 2-3 minutes), followed by a one-time interview conducted through Microsoft teams. During the interview, we will ask you about your perspectives on immunizing babies against RSV. We will also ask questions about how RSV information could be shared with parents. The interview will last about 40 minutes.